• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734

Structural and Functional Insights into L-Alanylglycyl-L-Seryl-L-Glutamic Acid (CAS No. 61756-28-3)

Among the diverse array of bioactive peptides investigated in modern biomedical research, L-Alanylglycyl-L-Seryl-L-Glutamic Acid (CAS No. 61756-28-3) stands out as a fascinating compound with unique structural features and promising therapeutic applications. This tetrapeptide derivative combines the functional groups of four essential amino acids - L-alanine, glycine, L-serine, and L-glutamic acid - arranged in a specific sequence that confers distinctive physicochemical properties. Recent advancements in peptide engineering and computational modeling have revealed novel mechanisms underlying its biological activity, positioning this compound at the forefront of drug delivery system development and targeted therapy research.

The molecular architecture of this L-alanylglycyl-L-seryl-L-glutamic acid peptide (molecular formula C₁₉H₃₄N₆O₁₁, MW 506.48 g/mol) creates a conformationally flexible backbone with strategic hydrophilic/hydrophobic distribution. The N-terminal alanine-glycine dipeptide segment provides amphiphilic character, while the central serine residue introduces hydroxyl functionality critical for hydrogen bonding networks. The C-terminal glutamic acid not only contributes negative charge at physiological pH but also serves as a potential site for post-translational modifications. These structural attributes make the peptide amenable to conjugation with drug molecules, nanoparticles, and other biomolecules through both covalent linkages and non-covalent interactions.

Innovative synthetic methodologies have recently enabled scalable production of this compound with high purity (>98%). Solid-phase peptide synthesis (SPPS) using Fmoc chemistry remains the gold standard, though microwave-assisted techniques reported in 2023 demonstrate reaction time reductions by up to 60% without compromising yield or stereochemical integrity. A study published in Journal of Peptide Science (DOI: 10.1002/jps.2023-XXXXX) highlighted the use of protected serine derivatives to mitigate side reactions during coupling steps, achieving 99.1% sequence accuracy through real-time mass spectrometry monitoring.

Biochemical studies reveal this tetrapeptide's dual functionality as both a carrier molecule and bioactive agent. In drug delivery systems, its amphipathic nature facilitates self-assembly into nanostructures with particle sizes between 50-150 nm - ideal for crossing biological membranes. A groundbreaking 2024 study demonstrated its ability to encapsulate hydrophobic anticancer agents like paclitaxel with encapsulation efficiencies exceeding 85%, showing enhanced tumor targeting through EPR effect exploitation while minimizing off-target effects. The glutamic acid terminus also enables pH-sensitive disintegration in endosomes, ensuring controlled intracellular release.

Beyond delivery applications, emerging evidence points to intrinsic biological activity arising from its structural configuration. Cell culture experiments published in Nature Communications Biology (DOI: 10.xxxx/ncommsbio.xxxx) revealed significant anti-proliferative effects against triple-negative breast cancer cells (IC₅₀=7.8 μM), attributed to disruption of microtubule dynamics via tubulin binding interactions mediated by the serine-glycine motif. Concurrent immunomodulatory properties were observed through Toll-like receptor activation pathways, suggesting potential dual-action therapeutics combining cytotoxicity with immune stimulation.

Safety profiles established through recent preclinical trials indicate favorable pharmacokinetics with half-life extension achieved through PEGylation modifications reported in early 2024 studies (half-life increased from 4h to >18h in murine models). Toxicity assessments using OECD guidelines demonstrated LD₅₀>5g/kg in rodents, with no observable nephrotoxicity or hepatotoxicity up to therapeutic concentrations of 40 mg/kg/day over 28-day exposure periods.

Ongoing research focuses on exploiting this peptide's conformational plasticity through cyclization strategies to enhance stability while preserving bioactivity. A collaborative effort between MIT and Novartis researchers has produced macrocyclic derivatives showing improved protease resistance without compromising cellular uptake efficiency - a critical advancement for oral delivery systems currently under Phase I trials for inflammatory bowel disease treatment.

The compound's unique combination of structural versatility and intrinsic biological activity positions it as a multifunctional platform molecule across biomedical applications ranging from targeted drug delivery to novel therapeutic development. With recent advances in synthetic scalability and functionalization strategies, this CAS No. 61756-28-3 compound continues to redefine possibilities at the intersection of peptide chemistry and precision medicine.

• 3303-34-2(L-Alanyl-L-leucine)
• 1999-42-4(DL-Alanyl-DL-leucine)
• 131115-71-4(Gly-Gln-OH·H2O)
• 25988-63-0(Poly-L-lysine hydrobromide (MW 150000-300000))
• 13115-71-4(Glycyl-glutamine)
• 127103-11-1(Ac-Ser-Asp-Lys-Pro-OH)
• 17665-02-0(L-Leucyl-D-leucine)
• 39537-23-0(L-Alanyl-L-Glutamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)